Palisade Bio Inc Stock Price, News & Analysis

Palisade Bio, Inc. (Nasdaq: PALI) announced significant results from a pooled analysis of its studies on LB1148, a protease inhibitor aimed at reducing postoperative adhesions in bowel resection surgeries. The analysis demonstrated a 72% reduction in adhesion formation and 93% reduction in adhesion severity. Notably, the incidence of adhesions in the placebo group aligned with published rates of 89% and over 90%. LB1148 has received Fast Track designation from the FDA, highlighting its potential to address a critical unmet medical need. A conference call is scheduled for March 16, 2022.

Palisade Bio (Nasdaq: PALI) is presenting pivotal data on post-surgical intraabdominal adhesions at the upcoming SAGES 2022 Annual Meeting on March 16. The ePoster, titled "Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148," highlights the significant unmet medical need, with nearly 7 million surgeries annually in the U.S. and $2 billion spent on treatment. The company aims to demonstrate how LB1148 can address these complications and improve recovery outcomes.

Palisade Bio, Inc. (Nasdaq: PALI) announced its participation at the Biocom Global Life Science Partnering Conference on February 24, 2022, with CEO Tom Hallam presenting at 11:30 a.m. PT. The company is advancing its lead product candidate, LB1148, towards global Phase 3 studies aimed at restoring bowel function post-GI surgery. Positive Phase 2 trial results indicated safety and significant improvement in recovery time. The in-person conference will bring together key industry stakeholders at The Lodge at Torrey Pines, San Diego, fostering valuable partnerships.

Palisade Bio has expanded its management team by appointing Robert McRae as Senior Vice President, Operations and Strategic Development. McRae brings extensive experience in biotech and will focus on internal operations and corporate strategy as the company prepares for Phase 3 clinical trials of its lead product, LB1148, which aims to address postoperative gastrointestinal complications. Additionally, equity grants covering 100,000 shares have been made to two new employees under the 2021 Inducement Plan.

Palisade Bio (Nasdaq: PALI) announced that data from the pooled analysis of studies LBS-IST-POI-101 and LBS-POI-201-CN will be presented at the SAGES 2022 Annual Meeting. The presentation will cover the incidence and severity of post-surgical intraabdominal adhesions after bowel resection surgery, focusing on the effects of the enteral protease inhibitor LB1148. Notably, LB1148 has previously shown a significant 1.1-day improvement in bowel function recovery. The company's innovative lead drug is progressing towards Phase 3 trials.

Palisade Bio, a clinical stage biopharmaceutical company focused on gastrointestinal therapies, will present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase from January 10-13 and January 10-12, 2022, respectively. Their lead program, LB1148, has demonstrated significant results in a Phase 2 trial, showing a 1.1-day improvement in bowel function recovery post-GI surgery. Presentations will be available through their investor relations website. These events highlight Palisade's commitment to advancing innovative treatments for GI complications.

Palisade Bio has announced the issuance of U.S. Patent No. 11,202,768, enhancing its patent portfolio for LB1148, aimed at treating postoperative ileus and adhesions. The patent, effective December 21, 2021, provides coverage until 2037, supporting ongoing clinical trials. LB1148 has shown promising results in Phase 2 trials, significantly improving bowel function recovery post-surgery. The company continues to seek additional patent protections globally to fortify its intellectual property, with FDA Fast Track Designation already granted for LB1148.

Palisade Bio (NASDAQ: PALI) has announced the European Patent Office (EPO) will publish a patent covering its lead drug, LB1148, on December 22, 2021, offering protection until 2035. This patent strengthens IP protection globally, complementing existing patents in the US and other countries. The company is focused on advancing LB1148 through clinical trials aimed at treating acute and chronic gastrointestinal complications. Previous Phase 2 trials showed LB1148's safety and efficacy, indicating significant improvements in bowel function and reduced ICU stays.

Palisade Bio, Inc. (NASDAQ: PALI) announced the equity grants of options covering 150,000 shares to three new employees under its 2021 Inducement Plan. The grants were made as an inducement for these employees to join the company. Nick McCoy has been appointed as VP of Clinical Operations, bringing extensive experience in conducting clinical studies crucial to Palisade's operations. The options granted will vest over three years, contingent on the employees' continued service. Palisade Bio is advancing therapeutic solutions for gastrointestinal complications and is moving its lead asset, LB1148, towards Phase 3 studies.